🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccines in the pandemic and has focused upon alleged deaths following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to announce radical changes to the childhood vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a significant shift that would put the US at odds with many the global community with insufficient data for improved outcomes. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A Shift at the Agency

The acting appointment might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood vaccine recommendations in the US in order to be more like the Danish model, a country with comprehensive healthcare and a citizenry roughly the size of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – traditionally the purview of Prasad, director of the FDA’s CBER – instead of medication approval.

Questions Over Expertise

The appointee has little discernible experience in medication creation, oversight or leadership, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “understand legal statutes and the research of medication creation”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who ran CBER have had.”

The drug center has an enormous portfolio at the FDA, she pointed out.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these have to be supervised,” Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant administrative element to the job, which manages in excess of 5,000 employees. “It is a massive administrative position, if you do it right,” Woodcock said.

Official Statement and Contentious Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on vaccines, a representative responded that the “inquiries are based on inaccurate assumptions”.

“This background is consistent with the duties of her position,” the representative explained, noting the months Dr. Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s new priority voucher program, a contentious one-day drug-approval program that reportedly worried her preceding directors. “How are these therapies being selected for this expedited pathway? Who is making the calls?” Dr. Howard said. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards more relaxed regulations of most medications, with the exception of immunizations.”

Documented History on Immunizations

With immunizations, Dr. Høeg has a more documented, if problematic, past, Howard observe. She authored a study using unverified public submissions to determine the frequency of heart inflammation following COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new administration encompassed changing regulations for novel immunizations and halting “non-essential” immunizations, she remarked after the election on a podcast. At the FDA, Høeg has allegedly proposed excluding young men from receiving Covid vaccinations.

“She’s an thorough dogmatist who starts off with her conclusions and tailors the evidence to accommodate the data in a extremely disingenuous, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|